CBD

The history of CBD is fascinating and stretches back thousands of years, although the molecule itself wasn't isolated until the 20th century. Cannabis as a plant has been used by humans for over 5,000 years, but the understanding of its specific chemical components is relatively new. CBD's journey from an obscure chemical compound to a global wellness phenomenon has been marked by scientific breakthroughs, legal hurdles, and cultural shifts. Today, CBD is a multi-billion dollar market, but this success is built on a long history of use, prohibition, and rediscovery.

In this article, we take you on a historical journey through the history of CBD and cannabis. We begin with the earliest records of cannabis use in ancient cultures, trace the scientific discovery of CBD in the 20th century, examine the dark years of cannabis prohibition, and explore CBD's modern renaissance. We conclude with a look at the current situation and future trends that will shape the CBD industry.

Cannabis in ancient civilizations

Cannabis is one of the oldest cultivated plants known to humankind. Archaeological findings suggest that cannabis was used in Central Asia over 10,000 years ago, initially for its fibers used to make textiles and ropes. The medicinal use of cannabis dates back at least 5,000 years. In China, the legendary Emperor Shennong mentions it in his pharmacological text around 2737. v.Chr. Cannabis was used as medicine for various ailments, including rheumatism, gout, and malaria. Cannabis seeds and oils were valued as food.

In ancient India, cannabis was part of Ayurvedic medicine and religious practices. It was mentioned as one of the five sacred plants in the Atharva Veda. Bhang, a cannabis drink, is still consumed at religious festivals today. Cannabis was also known in the Middle East and the Mediterranean. The Scythians, a nomadic people, used cannabis in ritual contexts. Herodotus described it in the 5th century. v.Chr. , like the Scythians who threw cannabis seeds onto hot stones and inhaled the fumes.

In ancient Egypt, cannabis was used medicinally, as evidenced by papyri. It was used to treat inflammation, glaucoma, and gynecological problems. The Romans also used cannabis, primarily for its fibers, but also medicinally. Pliny the Elder and Galen mentioned therapeutic applications. These ancient cultures utilized the entire plant without knowing the specific cannabinoids. They empirically observed the effects and developed applications based on generations of experience.

Middle Ages to the 19th century

During the Middle Ages, cannabis use continued in various cultures. In the Islamic world, cannabis was widespread as both medicine and a recreational drug, despite religious controversies surrounding its psychoactive effects. Avicenna, the renowned Persian physician, described cannabis in his medical canon in the 11th century. In Europe, cannabis was primarily cultivated for its fibers. Hemp ropes were essential for shipping. Medicinal use was limited but existed.

With colonial expansion, cannabis spread further. Spaniards and Portuguese brought hemp to America for fiber production. Hemp cultivation was widespread in the USA, and Founding Fathers like George Washington and Thomas Jefferson grew it. In the 19th century, cannabis experienced a resurgence in Western medicine. Irish physician William O'Shaughnessy studied cannabis in India and introduced it to European medicine. He documented its effectiveness in treating pain, cramps, and cholera.

Cannabis tinctures were sold in pharmacies and were included in the pharmacopoeias of many countries. Preparations from companies like Eli Lilly and Parke-Davis were available. Cannabis was prescribed for a wide variety of ailments. However, the composition of these preparations was inconsistent, as the active ingredients were unknown. This led to unpredictable effects. With the development of synthetic drugs in the early 20th century, cannabis began to disappear from conventional medicine before its chemistry was fully understood.

Scientific discovery of CBD

CBD was isolated in 1940 by American chemist Roger Adams at the University of Illinois. He extracted CBD from cannabis but did not fully determine its structure. At the same time, British chemist Alexander Todd also isolated cannabinoids. The precise chemical structure of CBD was not elucidated until 1963 by Israeli chemist Raphael Mechoulam and his team. Mechoulam is a key figure in cannabinoid research. A year later, in 1964, Mechoulam also isolated and structured THC, the psychoactive cannabinoid.

These discoveries were revolutionary, but they didn't yet provide an understanding of how these molecules work in the body. The endocannabinoid system wasn't discovered until the 1990s. In 1988, researchers identified the CB1 receptor in the brain, and in 1993, CB2 was discovered. This explained how cannabinoids exert physiological effects. The discovery of endogenous cannabinoids like anandamide in 1992 completed the picture. Suddenly, it became clear that the body has a system that interacts with cannabis compounds.

Mechoula's research opened doors to a scientific understanding of cannabis. He conducted early clinical trials, including a groundbreaking 1980 study that showed CBD reduced seizures in children with epilepsy. This study was small but prophetic for later developments. Despite these findings, cannabis research remained hampered by legal restrictions. Cannabis was illegal in most countries, and research was difficult and stigmatized. The scientific community was interested, but political and social factors slowed progress.

The dark years: Cannabis ban

The 20th century saw a dramatic shift in attitudes toward cannabis. In the United States, individual states began regulating cannabis in the 1910s, often with racist motives against Mexican immigrants. The Marijuana Tax Act of 1937 at the federal level made cannabis virtually illegal. Harry Anslinger, head of the Federal Bureau of Narcotics, led an intense anti-cannabis campaign based on racist and scientifically unfounded claims. Cannabis was demonized as a dangerous drug that led to violence and insanity.

The Controlled Substances Act of 1970 classified cannabis as a Schedule I drug, the highest level of restriction, implying no medical benefit and a high potential for abuse. This was despite recommendations from the Shafer Commission, which advocated for cannabis decriminalization. The UN Single Convention on Narcotic Drugs of 1961 classified cannabis similarly internationally. Many countries worldwide followed suit, prohibiting cannabis. This led to decades where cannabis possession resulted in imprisonment, ruined millions of lives, and stifled research.

The prohibition had devastating consequences. The War on Drugs, particularly in the US, led to mass incarceration, disproportionately affecting African American and Latino communities. Medical cannabis research stagnated. Patients who could benefit from cannabis were criminalized.The cultural stigma surrounding cannabis prevented rational discussion. Ironically, hemp, the non-psychoactive variety of cannabis, was also affected, even though it has no intoxicating properties. Only later was hemp treated in a more nuanced way.

Modern Renaissance and medical cannabis

The turning point came in the 1990s. California legalized medical cannabis in 1996 through Proposition 215, a landmark decision. Other US states followed suit. This opened up opportunities for patients and research, although federal law continued to prohibit cannabis, leading to legal complexities. In Europe, countries like the Netherlands, Portugal, and later Germany began implementing medical cannabis programs. Israel was a leader in cannabis research despite global restrictions, thanks to Mechoulam and others.

A turning point for CBD was the story of Charlotte Figi. Charlotte had Dravet syndrome, a severe form of epilepsy with hundreds of seizures a week. Conventional medications failed. In 2012, her parents tried CBD-rich cannabis oil. The seizures decreased dramatically. This story was widely reported in the media and inspired other families. The CBD strain was named Charlotte's Web. This catalyzed interest in CBD for epilepsy and other conditions. Parents of children with epilepsy began to fight for access to CBD.

This led to increased research. GW Pharmaceuticals developed Epidiolex, a pharmaceutical CBD preparation. Clinical trials demonstrated efficacy in Dravet and Lennox-Gastaut syndromes. In 2018, the FDA approved Epidiolex, the first cannabis-derived drug in the US. This was a breakthrough, scientifically and medically legitimizing CBD. The World Health Organization declared in 2018 that CBD is safe and has no potential for abuse. This official recognition helped reduce stigma and influence policy.

The CBD boom of the 21st century

The current CBD boom really began after the 2018 US Farm Bill, which legalized hemp at the federal level. This opened the floodgates for CBD products. The market exploded. CBD oils, capsules, gummies, creams, coffee, even CBD-infused dog toys flooded the market. Celebrities and athletes endorsed CBD. Social media was saturated with CBD content. The global CBD market was estimated to be worth billions, and forecasts predicted exponential growth.

This rapid expansion had its downsides. Regulation lagged behind. Many products were mislabeled, contained less CBD than claimed, or were contaminated. The FDA struggled to establish guidelines. Exaggerated health claims were widespread, with some companies marketing CBD as a cure for everything from cancer to autism. Reputable scientists and health experts warned against the hype and emphasized the need for more research.

Nevertheless, the boom also spurred positive developments. More research funding flowed into cannabis studies. Universities established cannabis research programs. Stigma continued to decrease. People began to talk openly about cannabis use. The industry professionalized with quality standards and testing protocols. Large pharmaceutical companies began investing in cannabis research. Countries worldwide reconsidered cannabis policies, with legalization in Canada and Uruguay, and decriminalization elsewhere. CBD became culturally mainstream.

Current legal landscape

The legal situation surrounding CBD is currently a patchwork. In the EU, CBD derived from hemp with less than 0.2 percent THC is generally legal, but novel food regulations create uncertainty.Germany, France, the UK, and others have their own nuances. Switzerland allows higher THC levels. In the US, hemp CBD has been federally legal since 2018, but FDA regulation for food and dietary supplements is unclear. Individual states have their own laws. Outside the West, laws vary widely, from liberal to very restrictive.

Internationally, the 2020 UN decision to reclassify cannabis signaled a shift. More countries are considering or implementing medical cannabis programs. The global trend is toward liberalization, but progress is uneven. Some countries maintain strict prohibitions. The legal complexities remain a challenge for both industry and consumers. Traveling internationally with CBD is risky. The coming years will bring further clarification and, hopefully, harmonization.

The research landscape is improving. More countries are permitting cannabis research. Large clinical trials are underway for various applications of CBD. Private investment and government funding are supporting research. The scientific literature on CBD is growing exponentially. We are at the beginning of a better understanding of CBD and the endocannabinoid system. The coming decades will likely reveal which of the many claims about CBD are substantiated and which new medical applications will be discovered.

Summary

The history of CBD begins with millennia of cannabis use in ancient cultures such as China, India, and Egypt for medicinal and religious purposes, before cannabis was demonized by racially motivated prohibitions in the 20th century. CBD was scientifically discovered in 1940, its structure was elucidated by Raphael Mechoulam in 1963, and the endocannabinoid system was identified in the 1990s. The modern renaissance began with the legalization of medical cannabis starting in 1996 and the viral story of Charlotte Figi, which led to the FDA approval of Epidiolex in 2018. The 2018 US Farm Bill catalyzed a global CBD boom, although the legal landscape remains complex and further research is needed to fully understand CBD's potential.